Sitagliptin/Metforminhydrochlorid "Medical Valley" 50+1000 mg filmovertrukne tabletter Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin/metforminhydrochlorid "medical valley" 50+1000 mg filmovertrukne tabletter

medical valley invest ab - metforminhydrochlorid, sitagliptinhydrochlorid - filmovertrukne tabletter - 50+1000 mg

Sitagliptin "Laurus" 100 mg filmovertrukne tabletter Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin "laurus" 100 mg filmovertrukne tabletter

laurus generics gmbh - sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 100 mg

Sitagliptin "Laurus" 50 mg filmovertrukne tabletter Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin "laurus" 50 mg filmovertrukne tabletter

laurus generics gmbh - sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 50 mg

Sitagliptin "Reddy" 100 mg filmovertrukne tabletter Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin "reddy" 100 mg filmovertrukne tabletter

reddy holding gmbh - sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 100 mg

Sitagliptin "Reddy" 50 mg filmovertrukne tabletter Дания - датски - Lægemiddelstyrelsen (Danish Medicines Agency)

sitagliptin "reddy" 50 mg filmovertrukne tabletter

reddy holding gmbh - sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 50 mg

Trulicity Европейски съюз - датски - EMA (European Medicines Agency)

trulicity

eli lilly nederland b.v. - dulaglutide - diabetes mellitus, type 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for undersøgelsens resultater med hensyn til kombinationer, effekt på glykæmisk kontrol og hjerte-kar-hændelser, og de befolkninger, der studerede, se afsnit 4. 4, 4. 5 og 5.